Astrazeneca Plc $AZN Shares Sold by Traveka Wealth LLC

Traveka Wealth LLC cut its holdings in Astrazeneca Plc (NYSE:AZN) by 50.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,417 shares of the company’s stock after selling 3,481 shares during the quarter. Traveka Wealth LLC’s holdings in Astrazeneca were worth $674,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. MV Capital Management Inc. acquired a new stake in Astrazeneca in the 4th quarter valued at $26,000. Reflection Asset Management acquired a new position in Astrazeneca during the fourth quarter worth $31,000. Lloyd Advisory Services LLC. acquired a new position in Astrazeneca during the fourth quarter worth $35,000. Basepoint Wealth LLC acquired a new position in Astrazeneca during the fourth quarter worth $44,000. Finally, Acumen Wealth Advisors LLC purchased a new position in Astrazeneca during the fourth quarter valued at $47,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Stock Up 1.6%

Shares of NYSE:AZN opened at $188.58 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The business has a fifty day moving average of $184.66 and a two-hundred day moving average of $187.05. The stock has a market cap of $292.47 billion, a P/E ratio of 28.32, a PEG ratio of 1.64 and a beta of 0.25. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, research analysts expect that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on AZN shares. Weiss Ratings lowered shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.